Cargando…
CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia
BACKGROUND: Acquired aplastic anemia (AA) is characterized by deficiency or dysfunction of the bone marrow (BM) microenvironment. However, little is known about the impairment of BM-derived mesenchymal stem cells (MSCs) in AA patients. METHODS: We used Illumina HiSeqTM 2000 sequencing, quantitative...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540520/ https://www.ncbi.nlm.nih.gov/pubmed/28764810 http://dx.doi.org/10.1186/s13287-017-0620-4 |
_version_ | 1783254649851084800 |
---|---|
author | Lu, Shihong Ge, Meili Zheng, Yizhou Li, Jianping Feng, Xiaoming Feng, Sizhou Huang, Jinbo Feng, Ying Yang, Donglin Shi, Jun Chen, Fang Han, Zhongchao |
author_facet | Lu, Shihong Ge, Meili Zheng, Yizhou Li, Jianping Feng, Xiaoming Feng, Sizhou Huang, Jinbo Feng, Ying Yang, Donglin Shi, Jun Chen, Fang Han, Zhongchao |
author_sort | Lu, Shihong |
collection | PubMed |
description | BACKGROUND: Acquired aplastic anemia (AA) is characterized by deficiency or dysfunction of the bone marrow (BM) microenvironment. However, little is known about the impairment of BM-derived mesenchymal stem cells (MSCs) in AA patients. METHODS: We used Illumina HiSeqTM 2000 sequencing, quantitative real-time polymerase chain reaction (qRT-PCR), flow cytometry (FCM), and Western blotting to test the expression of CD106 gene (vascular cell adhesion molecule 1 (VCAM1)) and CD106 protein of BM-MSCs. Furthermore, we used hematoxylin and eosin (H&E) and histochemical staining analysis, immunofluorescence, and the formation of capillary-like structures to analyze capillary tube-like formation in vitro; we also used the Matrigel plug assay to test in vivo vasculogenesis, and an assay of colony forming units (CFUs) and colony-forming unit-megakaryocyte (CFU-MK) to detect the support function of MSCs in vitro. The in vivo engraftment of CD34(+) cells and MSCs in NOD/SCID mice was tested by FACS and survival assay; the expression of NF-κB was tested by NanoPro analysis and immunofluorescence. NF-κB-regulated CD106 gene (VCAM1) was confirmed by tumor necrosis factor alpha (TNF-α)-stimulated and lipopolysaccharide (LPS)-stimulated MSCs, blockade assay, and immunofluorescence. RESULTS: Here, we report that BM-MSCs from AA patients exhibited downregulation of the CD06 gene (VCAM1) and low expression of CD106 in vitro. Further analysis revealed that CD106(+) MSCs from both AA patients and healthy controls had increased potential for in vitro capillary tube-like formation and in vivo vasculogenesis compared with CD106(–) MSCs, and the results were similar when healthy MSCs were compared with AA MSCs. CD106(+) MSCs from both AA patients and healthy controls more strongly supported in vitro growth and in vivo engraftment of CD34(+) cells in NOD/SCID mice than CD106(–) MSCs, and similar results were obtained when healthy MSCs and AA MSCs were compared. The expression of NF-κB was decreased in AA MSCs, and NF-κB regulated the CD106 gene (VCAM1) which supported hematopoiesis. CONCLUSIONS: These results revealed the effect of CD106 and NF-κB in BM failure of AA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-017-0620-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5540520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55405202017-08-07 CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia Lu, Shihong Ge, Meili Zheng, Yizhou Li, Jianping Feng, Xiaoming Feng, Sizhou Huang, Jinbo Feng, Ying Yang, Donglin Shi, Jun Chen, Fang Han, Zhongchao Stem Cell Res Ther Research BACKGROUND: Acquired aplastic anemia (AA) is characterized by deficiency or dysfunction of the bone marrow (BM) microenvironment. However, little is known about the impairment of BM-derived mesenchymal stem cells (MSCs) in AA patients. METHODS: We used Illumina HiSeqTM 2000 sequencing, quantitative real-time polymerase chain reaction (qRT-PCR), flow cytometry (FCM), and Western blotting to test the expression of CD106 gene (vascular cell adhesion molecule 1 (VCAM1)) and CD106 protein of BM-MSCs. Furthermore, we used hematoxylin and eosin (H&E) and histochemical staining analysis, immunofluorescence, and the formation of capillary-like structures to analyze capillary tube-like formation in vitro; we also used the Matrigel plug assay to test in vivo vasculogenesis, and an assay of colony forming units (CFUs) and colony-forming unit-megakaryocyte (CFU-MK) to detect the support function of MSCs in vitro. The in vivo engraftment of CD34(+) cells and MSCs in NOD/SCID mice was tested by FACS and survival assay; the expression of NF-κB was tested by NanoPro analysis and immunofluorescence. NF-κB-regulated CD106 gene (VCAM1) was confirmed by tumor necrosis factor alpha (TNF-α)-stimulated and lipopolysaccharide (LPS)-stimulated MSCs, blockade assay, and immunofluorescence. RESULTS: Here, we report that BM-MSCs from AA patients exhibited downregulation of the CD06 gene (VCAM1) and low expression of CD106 in vitro. Further analysis revealed that CD106(+) MSCs from both AA patients and healthy controls had increased potential for in vitro capillary tube-like formation and in vivo vasculogenesis compared with CD106(–) MSCs, and the results were similar when healthy MSCs were compared with AA MSCs. CD106(+) MSCs from both AA patients and healthy controls more strongly supported in vitro growth and in vivo engraftment of CD34(+) cells in NOD/SCID mice than CD106(–) MSCs, and similar results were obtained when healthy MSCs and AA MSCs were compared. The expression of NF-κB was decreased in AA MSCs, and NF-κB regulated the CD106 gene (VCAM1) which supported hematopoiesis. CONCLUSIONS: These results revealed the effect of CD106 and NF-κB in BM failure of AA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13287-017-0620-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-01 /pmc/articles/PMC5540520/ /pubmed/28764810 http://dx.doi.org/10.1186/s13287-017-0620-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Lu, Shihong Ge, Meili Zheng, Yizhou Li, Jianping Feng, Xiaoming Feng, Sizhou Huang, Jinbo Feng, Ying Yang, Donglin Shi, Jun Chen, Fang Han, Zhongchao CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia |
title | CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia |
title_full | CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia |
title_fullStr | CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia |
title_full_unstemmed | CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia |
title_short | CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia |
title_sort | cd106 is a novel mediator of bone marrow mesenchymal stem cells via nf-κb in the bone marrow failure of acquired aplastic anemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540520/ https://www.ncbi.nlm.nih.gov/pubmed/28764810 http://dx.doi.org/10.1186/s13287-017-0620-4 |
work_keys_str_mv | AT lushihong cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT gemeili cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT zhengyizhou cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT lijianping cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT fengxiaoming cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT fengsizhou cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT huangjinbo cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT fengying cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT yangdonglin cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT shijun cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT chenfang cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia AT hanzhongchao cd106isanovelmediatorofbonemarrowmesenchymalstemcellsvianfkbinthebonemarrowfailureofacquiredaplasticanemia |